United Therapeutics Corp
NASDAQ:UTHR

Watchlist Manager
United Therapeutics Corp Logo
United Therapeutics Corp
NASDAQ:UTHR
Watchlist
Price: 363.65 USD 1.13% Market Closed
Market Cap: 16.2B USD
Have any thoughts about
United Therapeutics Corp?
Write Note

United Therapeutics Corp
Total Current Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

United Therapeutics Corp
Total Current Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Current Assets CAGR 3Y CAGR 5Y CAGR 10Y
United Therapeutics Corp
NASDAQ:UTHR
Total Current Assets
$4B
CAGR 3-Years
19%
CAGR 5-Years
16%
CAGR 10-Years
14%
Abbvie Inc
NYSE:ABBV
Total Current Assets
$27.8B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
5%
Gilead Sciences Inc
NASDAQ:GILD
Total Current Assets
$13.1B
CAGR 3-Years
-2%
CAGR 5-Years
-14%
CAGR 10-Years
0%
Amgen Inc
NASDAQ:AMGN
Total Current Assets
$26.8B
CAGR 3-Years
3%
CAGR 5-Years
-3%
CAGR 10-Years
-3%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Total Current Assets
$9.8B
CAGR 3-Years
3%
CAGR 5-Years
15%
CAGR 10-Years
20%
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Total Current Assets
$19.3B
CAGR 3-Years
12%
CAGR 5-Years
22%
CAGR 10-Years
24%
No Stocks Found

United Therapeutics Corp
Glance View

Market Cap
16.2B USD
Industry
Biotechnology
Economic Moat
Narrow

In the landscape of biotechnology, United Therapeutics Corp. has crafted a compelling narrative centered around innovation and transformation, principally targeting life-threatening conditions. Founded in 1996 by Martine Rothblatt, the company's inception was motivated by the urgent need to find solutions for her daughter's rare disease, pulmonary arterial hypertension (PAH). Over the years, United Therapeutics has stayed true to its pioneering ethos, focusing on creating and commercializing unique therapies that address the needs of patients with severe and often unmet health challenges. The core of its operations revolves around developing drugs that enhance survival and quality of life for individuals afflicted by PAH and other similar illnesses. Such dedication to research and pharmaceutical development has fostered a robust product pipeline, including therapeutics like Remodulin and Tyvaso, which play pivotal roles in the company's revenue generation. Financially, United Therapeutics sustains its momentum through a blend of strong patent portfolios and strategic market positioning, ensuring both competitive advantage and an ongoing revenue stream. By maintaining a keen focus on specific niches within the biotechnology sector, the company minimizes competition while maximizing the impact of its therapeutic solutions. Its business model thrives on the supply of specialized medications, which, given their critical nature, command premium pricing. Yet, United Therapeutics doesn’t solely pivot around drug sales; it is deeply invested in the future of medicine, notably venturing into areas like organ manufacturing and xenotransplantation, where it seeks to address broader and more complex health challenges. Through a blend of innovation, strategic partnerships, and diversification into emerging medical fields, United Therapeutics continues to cement its reputation as a leader in biotechnological advancement.

UTHR Intrinsic Value
375 USD
Undervaluation 3%
Intrinsic Value
Price

See Also

What is United Therapeutics Corp's Total Current Assets?
Total Current Assets
4B USD

Based on the financial report for Sep 30, 2024, United Therapeutics Corp's Total Current Assets amounts to 4B USD.

What is United Therapeutics Corp's Total Current Assets growth rate?
Total Current Assets CAGR 10Y
14%

Over the last year, the Total Current Assets growth was 16%. The average annual Total Current Assets growth rates for United Therapeutics Corp have been 19% over the past three years , 16% over the past five years , and 14% over the past ten years .

Back to Top